Related references
Note: Only part of the references are listed.Integrative prognostic risk score in acute myeloid leukemia with normal karyotype
Frederik Damm et al.
BLOOD (2011)
WT1 Synonymous Single Nucleotide Polymorphism rs16754 Correlates With Higher mRNA Expression and Predicts Significantly Improved Outcome in Favorable-Risk Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Phoenix A. Ho et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Carlos Santamaria et al.
ANNALS OF HEMATOLOGY (2010)
FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Susan P. Whitman et al.
BLOOD (2010)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia
Giovanni Del Poeta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia
Frederik Damm et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study
Heiko Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination
Viggo F. Van Tendeloo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
AML in older patients: Are we making progress?
Elihu Estey
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group
Verena Ingeborg Gaidzik et al.
BLOOD (2009)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
Carlos M. Santamaria et al.
BLOOD (2009)
Clinical implications of molecular genetic aberrations in acute myeloid leukemia
Sebastian Scholl et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
Daniela Cilloni et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome
Jana Markova et al.
LEUKEMIA & LYMPHOMA (2009)
WT1 monitoring in core binding factor AML: Comparison with specific chimeric products
Adriana Lasa et al.
LEUKEMIA RESEARCH (2009)
WT1 Expression at Diagnosis Does Not Predict Survival in Pediatric AML: A Report From the Children's Oncology Group
Suzie A. Noronha et al.
PEDIATRIC BLOOD & CANCER (2009)
Independent prognostic factors for AML outcome
D. Grimwade et al.
Hematology-American Society of Hematology Education Program (2009)
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease
Adam J. Mead et al.
BLOOD (2008)
Molecular characterization of acute myeloid leukemia
Konstanze Doehner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Mutation of the Wilms' Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party
Priya Virappane et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia
Patricia C. Rodrigues et al.
PEDIATRIC BLOOD & CANCER (2007)
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML):: biologic and clinical features
Brunangelo Falini et al.
BLOOD (2007)
Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML
K. Summers et al.
LEUKEMIA (2007)
The many facets of the Wilms' tumour gene, WT1
Peter Hohenstein et al.
HUMAN MOLECULAR GENETICS (2006)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
H Kantarjian et al.
CANCER (2006)
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
S Schnittger et al.
BLOOD (2005)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy
V Gupta et al.
CANCER (2005)
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program
J Gabert et al.
LEUKEMIA (2003)
Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia
M Garg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)